Can Fite Biopharma (STU:CF5) Beta: N/A (As of Jul. 06, 2026)


STU:CF5 Can Fite Biopharma Ltd STU:CF5
52 GF Score
Price €101.00
GF Value €163.41
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), Can Fite Biopharma's Beta is Not available.


Can Fite Biopharma  (STU:CF5) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Can Fite Biopharma Beta Related Terms


Can Fite Biopharma Beta Historical Data

* Premium members only.

The historical data trend for Can Fite Biopharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biopharma Beta Chart

Can Fite Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.04 0.52 -0.48 -0.29

Can Fite Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.36 -0.48 -0.23 -0.29

STU:CF5 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Can Fite Biopharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biopharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Beta distribution charts can be found below:

* The bar in red indicates where Can Fite Biopharma's Beta falls into.


STU:CF5
52GF Score
Can Fite Biopharma Ltd STU:CF5
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Can Fite Biopharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Can Fite Biopharma (STU:CF5) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of €101.00 is trading 38.2% below its estimated GF Value™ of €163.41.

Key valuation signals for STU:CF5:

  • Beta: N/A
  • GF Value™: €163.41 vs. price of €101.00 (38.2% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the STU:CF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Can Fite Biopharma Business Description

Other Exchanges CANF:USACANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
52GF Score

Get the complete analysis for STU:CF5

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€101.00
Price
€163.41
GF Value